Dicot's study results were presented at European Society for Sexual Medicine
Press release: Uppsala, March 11, 2022. The pharmaceutical company Dicot announces that the results showing the long-term effect of the drug candidate LIB-01 were presented at the European Society for Sexual Medicine's (ESSM) annual congress.Dicot has previously announced that a submitted abstract, with results from animal studies demonstrating Dicot's drug candidate's long-term effect, was selected to be presented at ESSM's annual congress in 2022. ESSM is the leading scientific organization in sexual medicine whose annual congress brings together prominent researchers and doctors from